Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | GRN | P28799 | 2/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041607 | 1.00 | MME (0.37) | MMEUSP30MMEL1ALPLGRN | |
| SCHEMBL23051964 | 0.91 | MME (0.34) | MMEUSP30MMEL1ALPLMET | |
| SCHEMBL23041498 | 0.91 | MME (0.36) | MMEUSP30MMEL1PHGDH | |
| SCHEMBL23041497 | 0.91 | MME (0.36) | MMEUSP30MMEL1PHGDH | |
| SCHEMBL23041388 | 0.91 | MME (0.36) | MMEUSP30MMEL1PHGDH | |
| SCHEMBL23041387 | 0.91 | MME (0.36) | MMEUSP30MMEL1PHGDH | |
| SCHEMBL23041442 | 0.89 | PHGDH (0.35) | MMEUSP30MMEL1ALPLMET | |
| SCHEMBL23041445 | 0.89 | PHGDH (0.35) | MMEUSP30MMEL1ALPLMET | |
| SCHEMBL23051965 | 0.88 | CNR2 (0.34) | MMEUSP30PHGDH | |
| SCHEMBL28721016 | 0.88 | CNR2 (0.34) | MMEUSP30PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | disclosed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, TMEM161A, TMEM164 | MME 4464/4885USP30 2666/4885MMEL1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.